WNT蛋白治疗促进不稳定种植体周围骨形成
在去卵巢大鼠模型中,将50枚钛种植体植入过大骨创并功能负载,一半用脂质体WNT3A处理,一半用PBS对照。结果PBS组种植体发生纤维包裹,而L-WNT3A组显著增加增殖和成骨标志物表达,早期新骨形成并提高界面刚度。
要点
- 不稳定种植体在功能负载下易发生纤维包裹而非骨结合。
- 局部应用脂质体WNT3A可促进种植体周围新骨形成。
- L-WNT3A处理两周后种植体界面刚度较PBS组更高。
核心结论
- 在大鼠模型中,不稳定种植体发生纤维包裹,而局部应用L-WNT3A可显著增加种植体周围骨量和界面刚度。
研究设计与样本
- 采用自身对照(分口)设计,在去卵巢大鼠模型中植入50枚钛种植体于过大骨创,并施加功能负载。
- 一半种植体接受脂质体WNT3A治疗,另一半接受含PBS的相同脂质体制剂。
- 通过有限元建模、组织学、分子、细胞及显微CT分析,在植入后第3、7、14天评估。
主要发现
- 有限元分析预测种植体周围应变水平不利于新骨形成。
- PBS处理种植体经显微CT、组织学和定量免疫组化证实发生纤维包裹。
- L-WNT3A处理组增殖标志物PCNA和成骨标志物Runx2、Osterix表达显著增加。
- L-WNT3A治疗后一周可见新骨形成,两周后治疗间隙界面刚度高于PBS组。
临床怎么用
- 对于植入过大骨创的不稳定种植体,局部应用WNT3A治疗可能促进骨结合并提高初期稳定性。
局限性
- 本研究为去卵巢大鼠临床前模型,结果需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Our objective was to test the hypothesis that local delivery of a WNT protein therapeutic would support osseointegration of an unstable implant placed into an oversized osteotomy and subjected to functional loading. MATERIALS AND METHODS: Using a split-mouth design in an ovariectomized (OVX) rat model, 50 titanium implants were placed in oversized osteotomies. Implants were subjected to functional loading. One-half of the implants were treated with a liposomal formulation of WNT3A protein (L-WNT3A); the other half received an identical liposomal formulation containing phosphate-buffered saline (PBS). Finite element modeling estimated peri-implant strains caused by functional loading. Histological, molecular, cellular, and quantitative micro-computed tomographic (µCT) imaging analyses were performed on samples from post-implant days (PID) 3, 7, and 14. Lateral implant stability was quantified at PID 7 and 14. RESULTS: Finite element analyses predicted levels of peri-implant strains incompatible with new bone formation. Micro-CT imaging, histological, and quantitative immunohistochemical (IHC) analyses confirmed that PBS-treated implants underwent fibrous encapsulation. In those cases where the peri-implant environment was treated with L-WNT3A, µCT imaging, histological, and quantitative IHC analyses demonstrated a significant increase in expression of proliferative (PCNA) and osteogenic (Runx2, Osterix) markers. One week after L-WNT3A treatment, new bone formation was evident, and two weeks later, L-WNT3A-treated gaps had a stiffer interface compared to PBS-treated gaps. CONCLUSION: In a rat model, unstable implants undergo fibrous encapsulation. If the same unstable implants are treated with L-WNT3A at the time of placement, then it results in significantly more peri-implant bone and greater interfacial stiffness.
引用
- Coyac BR, Leahy B, Li Z, et al. Bone formation around unstable implants is enhanced by a WNT protein therapeutic in a preclinical in vivo model. Clin Oral Implants Res. 2020. PMID: 32881143. doi:10.1111/clr.13659
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。